Claims
- 1. A method for treating or preventing the development of Type II diabetes mellitus in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:
- 2. The method of claim 1 wherein the compound of formula (I) is topiramate.
- 3. The method of claim 1, wherein the therapeutically effective amount is from about 10 to 650 mg.
- 4. The method of claim 1, wherein the amount is of from about 16 to 325 mg once or twice daily.
- 5. A method for treating or preventing the development of Syndrome X (Insulin Resistance Syndrome, Metabolic Syndrome, or Metabolic Syndrome X) in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:
- 6. The method of claim 5 wherein the compound of formula (I) is topiramate.
- 7. The method of claim 5, wherein the therapeutically effective amount is from about 10 to 1000 mg daily.
- 8. The method of claim 5, wherein the therapeutically effective amount is from about 10 to 650 mg daily.
- 9. The method of claim 5, wherein the amount is of from about 16 to 325 mg once or twice daily.
- 10. A method for treating impaired oral glucose tolerance in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:
- 11. The method of claim 10, wherein the compound of formula (I) is topiramate.
- 12. (Canceled)
- 13. (Canceled).
- 14. (Canceled)
- 15. A method for treating or preventing the development of skin lesions associated with Type II diabetes mellitus or Syndrome X in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:
- 16. The method of claim 15, wherein the compound of formula (I) is topiramate.
- 17. The method of claim 15, wherein the therapeutically effective amount is from about 10 to 1000 mg daily.
- 18. The method of claim 15, wherein the therapeutically effective amount is from about 10 to 650 mg daily.
- 19. The method of claim 15, wherein the amount is of from about 16 to 325 mg once or twice daily.
- 20. A method for improving defective insulin sensitivity in a mammal in need thereof comprising administering to said mammal therapeutically effective amount of a compound of the formula I:
- 21. The method of claim 20, wherein the compound of formula (I) is topiramate.
- 22. (Canceled)
- 23. (Canceled)
- 24. (Canceled)
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. provisional application Serial No. 60/217,141 filed Jul. 07, 2000 and U.S. provisional application Serial No. 60/270,022 filed, Feb. 20, 2001, the contents of which are hereby incorporated by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60217141 |
Jul 2000 |
US |
|
60270022 |
Feb 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09900567 |
Jul 2001 |
US |
Child |
10843134 |
May 2004 |
US |